Stallergenes Greer: Hypersensitivity trials

The registry lists 13 Hypersensitivity studies with Stallergenes Greer as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 1Phase 2 3Phase 3 8No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral ImmunotherapyCompletedNCT01353079Phase 3Results posted
• Efficacy Study of Sublingual Immunotherapy to Treat Ragweed AllergiesCompletedNCT00599872Phase 3Results posted
• Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy TabletsCompletedNCT00418379Phase 3Results posted
• Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen RhinoconjunctivitisCompletedNCT00409409Phase 3Results posted
• Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen RhinoconjunctivitisCompletedNCT00367640Phase 2/3Results posted
• Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or AsthmaCompletedNCT04004351
• Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without ConjunctivitisCompletedNCT02295969
• Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick TestingCompletedNCT01964768Phase 3
• Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic RhinoconjunctivitisCompletedNCT01731249Phase 3
• Safety and Tolerability Study of Ragweed SLIT TabletsCompletedNCT01224834Phase 1
• Study of rBet v1 TabletsCompletedNCT00901914Phase 2
• A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust MitesCompletedNCT00660452Phase 3
• Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic PatientsTerminatedNCT00410930Phase 2